Evidence map›Paper›PMID 41326705›Full record

ArticleScientific reports2025

Comprehensive bulk and single-cell RNA sequencing uncovers senescence-associated biomarkers in therapeutic mesenchymal stem cells.

Emese Pekker, Erda Qorri, Márton Zs Enyedi, Valéria Szukacsov, Ferhan Ayaydin, Éva Szabó-Kriston, Bernadett Csányi, Mónika Mórocz, Farkas Sükösd, Endre Kiss-Tóth and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Emese Pekker *HCEMM-HUN-REN BRC Mutagenesis and Carcinogenesis Research Group, Institute of Genetics, HUN-REN Biological Research Centre, Szeged, Hungary.
Erda Qorri *HCEMM-HUN-REN BRC Mutagenesis and Carcinogenesis Research Group, Institute of Genetics, HUN-REN Biological Research Centre, Szeged, Hungary.
Márton Zs EnyediDelta Bio 2000 Ltd., Szeged, Hungary.
Valéria SzukacsovStem CellX Therapeutics Ltd., Szeged, Hungary.
Ferhan AyaydinHungarian Centre of Excellence for Molecular Medicine (HCEMM), Functional Cell Biology and Immunology Advanced Core Facility, University of Szeged, Szeged, Hungary.
Éva Szabó-KristonStem CellX Therapeutics Ltd., Szeged, Hungary.
Bernadett CsányiDelta Bio 2000 Ltd., Szeged, Hungary.
Mónika MóroczHCEMM-HUN-REN BRC Mutagenesis and Carcinogenesis Research Group, Institute of Genetics, HUN-REN Biological Research Centre, Szeged, Hungary.
Farkas SükösdDepartment of Pathology, Péterfy Sándor Street Hospital, Budapest, Hungary.
Endre Kiss-TóthStem CellX Therapeutics Ltd., Szeged, Hungary.
Lajos HaracskaHCEMM-HUN-REN BRC Mutagenesis and Carcinogenesis Research Group, Institute of Genetics, HUN-REN Biological Research Centre, Szeged, Hungary. haracska.lajos@brc.hu.

Funding

European Union's Horizon 2020 739593National Research, Development, and Innovation Office 2020-1.1.5-GYORSÍTÓSÁV-2021-00002
6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) hold great promise in cell therapy, but their effectiveness declines with repeated cell divisions due to senescence. Canines, sharing aging characteristics with humans, serve as a valuable model to study this process in a translational context. In the present study, we performed an in-depth characterization of senescence in canine MSCs using a combination of morphological, molecular, and transcriptomic analyses. Early (P2) and late-passage (P6) canine MSCs were characterized using a combination of senescence-associated β-galactosidase staining, cell cycle profiling, and both bulk and single-cell RNA sequencing to capture global transcriptional changes. By employing a passage-based in vitro approach, the present study demonstrates that late-passage cells (P6) compared to early-passage cells (P2) exhibit hallmark features of senescence, including morphological alterations, elevated SA-β-galactosidase activity, and considerable transcriptional changes. These changes were represented by significant upregulation of established senescence marker genes, alongside potential novel candidates and downregulation of genes associated with cell cycle progression and proliferation. Moreover, single-cell RNA sequencing uncovered heterogeneous distribution of senescent subpopulations, upregulation of SASP-related genes and reduced proliferation markers. Our findings demonstrate that combining classical markers with bulk and single-cell RNA sequencing facilitates senescent cell identification while improving quality control for clinical MSC samples.

Indexed as

Cellular SenescenceMesenchymal Stem CellsSequence Analysis, RNASingle-Cell AnalysisAnimalsBiomarkersCell CycleCell ProliferationCells, CulturedDogsGene Expression ProfilingHumansTranscriptomeBiomarkersAnimal modelBiomarkersMesenchymal stem cellSenescenceTranscriptomics

Identifiers

PMID41326705
PMCPMC12783114

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.